<DOC>
	<DOCNO>NCT01449071</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability Pharmacokinetics ( PK ) Epratuzumab Japanese subject moderate severe general SLE add standard care treatment trial .</brief_summary>
	<brief_title>Study Evaluating Pharmacokinetics Safety Epratuzumab Japanese Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Positive Antinuclear Antibody ( ANA ) Screening ( Visit 1 ) Current clinical diagnosis Systemic Lupus Erythematosus ( SLE ) American College Rheumatology ( ACR ) criterion Active moderate severe SLE activity demonstrate British Isles Lupus Assessment Group Index ( BILAG ) Active moderate severe SLE disease demonstrate Systemic Lupus Erythematosus Disease Activity Index ( SLEDAI ) total score stable SLE treatment Subjects breastfeeding , pregnant , plan become pregnant Subjects active , severe SLE disease activity involve renal system active , severe , neuropsychiatric SLE , define neuropsychiatric element score BILAG level A Serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-cell immunotherapy</keyword>
	<keyword>Epratuzumab</keyword>
</DOC>